Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Clasificación en acciones #37499
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Precio por acción
$0.05897422
Última sincronización: 2024-04-02
Capitalización bursátil
$1.64M
Cambio (1 día)
0.07%
Cambio (1 año)
-60.68%
País
CA
Comercio Intellipharmaceutics International Inc. (IPCI)

Categoría

Ganancias de Intellipharmaceutics International Inc. (IPCI)
Ganancias en Aug 2023 TTM: $-3.17M
Secondo gli ultimi rapporti finanziari di Intellipharmaceutics International Inc., gli utili attuali della società sono $-3.17M. Nel 2021, la società ha registrato un utile di $-2.89M, un aumento con respecto a agli utili del 2020, che erano di $-5.26M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Intellipharmaceutics International Inc. desde 1999 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-3.17M 9.75%
2022 $-2.89M 0.00%
2021 $-2.89M -45.11%
2020 $-5.26M 56.62%
2019 $-3.36M -75.57%
2018 $-13.75M 55.21%
2017 $-8.86M -12.68%
2016 $-10.14M 36.40%
2015 $-7.44M 92.83%
2014 $-3.86M -66.45%
2013 $-11.50M 135.54%
2012 $-4.88M 95.22%
2011 $-2.50M -56.34%
2010 $-5.73M -55.76%
2008 $-12.94M -56.95%
2007 $-30.07M -49.08%
2006 $-59.05M -25.61%
2005 $-79.37M 13.77%
2004 $-69.77M 173.92%
2003 $-25.47M 104.32%
2002 $-12.47M 36.27%
2001 $-9.15M 41.00%
2000 $-6.49M 0.00%
1999 0.00 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -166,580.77%
US
$-3.09B 97,328.60%
US
$-4.02B 126,654.91%
AU
$1.95B -61,664.34%
NL
- -
CH